Peer-to-Peer Review Requests for Fertility Medical Necessity
A complete guide to requesting, preparing for, and winning peer-to-peer reviews for IVF and ART medical necessity denials — including payer-specific contact methods, P2P timing windows, and the clinical arguments that produce the highest overturn rates.
A peer-to-peer review is a direct phone call between the treating REI physician and the payer's assigned medical director or clinical reviewer, requested after a utilization management denial of a fertility service — most commonly IVF retrieval (CPT 58970), embryo transfer (CPT 58974), or the associated embryology laboratory codes (89250–89281). It is not a formal appeal and does not require submitting a written claim correction. It is a clinical conversation between two physicians about one patient's specific medical situation, and when conducted correctly it produces overturn rates of 40–60% for fertility denials — significantly higher than first-level written appeals for the same denial types. Despite this, peer-to-peer reviews are chronically underutilized by fertility practices because the process is poorly understood, the payer-specific request windows are frequently missed, and the REI physicians who must conduct the call are often given inadequate preparation support by billing staff. This guide covers every element of the P2P process in fertility billing: when to request it, how to request it at each major payer, how to prepare the REI physician for the call, what clinical arguments to make, and how to document the outcome in the practice management system.
What a Peer-to-Peer Review Is — and What It Is Not
A peer-to-peer review is a utilization management (UM) process, not an appeal process. That distinction matters for how the request is submitted, who handles it on the payer side, and what the outcome means for claim processing. A P2P call happens when the treating physician contacts the payer's UM medical director to discuss a denial of authorization for a service that has been denied on prospective, concurrent, or retrospective review grounds. The UM medical director has the authority to reverse the clinical denial immediately on the call and issue a new authorization number — no formal appeal filing is required, no written documentation package needs to be submitted, and the authorization can in some cases be issued the same day as the call. This makes P2P review the fastest available resolution path for fertility UM denials when the request is timely and the physician is prepared.
A peer-to-peer review is not a substitute for a formal appeal and is not available at all points in the appeals process. Most payers only permit P2P requests within a defined window following the initial UM denial — typically 5 to 15 business days from the date of the UM determination letter, depending on the payer and whether the denial was prospective or concurrent. After that window closes, the practice must proceed through the formal first-level written appeal process, which takes 30–60 days versus the 1–3 days typically required to schedule and complete a P2P call. Missing the P2P window converts a fast, high-overturn-rate resolution pathway into a much slower written appeal process, which is why tracking the UM denial date and the applicable P2P request deadline is a front-end billing function that should be calendared the day the denial letter is received.
P2P Request Timing: The Critical Window Most Practices Miss
The P2P request window is independent of the formal appeal window and is typically much shorter. At most major commercial payers, the window to request a peer-to-peer review of a prospective fertility authorization denial is 10 to 15 business days from the date of the UM denial determination — not from the date the practice received the denial letter in the mail, and not from the date the denial EOB was issued. Practices that calendar the P2P deadline from the EOB date rather than the UM determination letter date routinely find themselves outside the P2P window because of the 5–10 day lag between the UM determination and EOB generation. For fertility cycles that were not authorized before the retrieval date, this timing error results in forfeiting the fastest available resolution pathway at the moment it is most urgently needed.
Critical: Calendar the P2P Deadline From the UM Determination Letter, Not the EOB
The peer-to-peer request window begins on the date of the utilization management denial determination, which is printed on the UM denial letter — not on the date the Explanation of Benefits is generated, and not on the date the practice receives the denial in the mail. At Aetna and United Healthcare, the prospective P2P request window is 10 business days from the UM determination date. At Cigna, it is 14 calendar days. At most BCBS state plans, it ranges from 5 to 10 business days. Because the EOB is typically generated 5 to 10 days after the UM determination, practices that calendar the P2P deadline from the EOB receipt date are already outside the P2P window at most payers before they have even identified the denial as P2P-eligible. Assign P2P deadline tracking to the authorization team — not the appeals team — and calendar the deadline on the day the UM denial letter is received, treating it as a same-day action item.
Payer-Specific P2P Process, Contact Methods, and Timelines
| Payer | P2P Request Window | How to Request | Who Conducts the Call | Key Process Notes |
|---|---|---|---|---|
| Aetna | 10 business days from UM determination date for prospective denials; 5 business days for concurrent review denials mid-cycle | Call the clinical reviewer line printed on the Aetna UM denial determination letter; for NaviMedic-managed cases, request through the NaviMedic provider line at the number on the NaviMedic denial letter — do not route NaviMedic cases through the standard Aetna clinical line as it creates a rerouting delay | Treating REI physician must conduct the call personally; billing staff or office managers may not conduct P2P calls on behalf of the physician — requests for P2P by non-physicians are declined and the P2P window continues to run | Aetna's UM medical directors review the case against CPB 0327 during the call; the REI physician should have the specific subsection of CPB 0327 applicable to the patient's diagnosis open during the call and be prepared to address each criterion the denial determination cited as unmet; overturn rate for fertility P2P calls with complete clinical preparation is approximately 50–55% based on denial management data across fertility practices |
| United Healthcare | 5 business days from UM determination date for prospective denials; 24 hours for urgent concurrent review denials | Call the UHC clinical reviewer line printed on the UM denial letter; do not submit P2P requests through the UHC provider portal — the portal does not route P2P requests to the UM clinical team | Treating REI physician must conduct the call; for group practices, only the physician who provided or ordered the denied service may conduct the P2P | UHC UM medical directors review against CDG CS-0037.D; the 5-business-day window is strict — UHC does not grant P2P extensions; if the practice received the denial letter outside the P2P window due to mail delay, document the postmark date and request a supervisor review; concurrent P2P for urgent fertility cycle management (e.g., imminent retrieval date) is available on an expedited 24-hour basis and should be requested the same day as the concurrent denial |
| Cigna | 14 calendar days from UM determination date | Submit P2P request through Cigna for Health Professionals portal at cignaforhp.com under "Authorization Request" then "Request Peer-to-Peer"; phone requests accepted at the clinical reviewer line on the denial letter as backup if the portal is unavailable | Treating REI physician; Cigna permits the ordering physician to conduct the call for referred fertility patients if the treating REI is unavailable within the P2P window — confirm with the Cigna clinical reviewer whether this applies to the specific case | Cigna matches the P2P request to Coverage Policy 0527; the 14-calendar-day window is more generous than Aetna and UHC but still routinely missed by practices that calendar from the EOB; Cigna Fertility carve-out patients (managed by WINFertility or Cigna's fertility benefit program) have separate P2P processes managed by the carve-out vendor — submit P2P requests through the carve-out vendor portal, not through standard Cigna channels |
| BCBS (state plans) | 5 to 10 business days depending on state plan; verify with home plan for BlueCard patients | State plan provider portal or clinical reviewer line on UM denial letter; BlueCard inter-plan P2P requests must route to the home plan's clinical team — contact the home plan's provider services line to obtain the correct P2P request contact for the member's home plan | Treating REI physician; some state BCBS plans accept P2P from the ordering physician for referred patients — verify on first call with the home plan's UM team | Home plan coverage criteria govern for all BlueCard inter-plan cases; state fertility mandate requirements apply based on the home plan's state (e.g., Illinois mandate applies to Illinois BCBS fully insured plans regardless of where the service was rendered); local state plan criteria and P2P contacts do not apply to BlueCard patients from out-of-state plans |
| Progyny | Not applicable as a standard P2P pathway; Progyny Smart Cycle disputes handled through clinical case manager escalation | Contact the assigned Progyny clinical case manager through the Progyny provider portal or by calling the Progyny provider services line printed on the prior authorization determination | Treating REI physician or fertility clinic medical director may request clinical escalation review; the process is a case manager clinical review, not a payer medical director P2P | Progyny clinical denials are rare for services within the authorized Smart Cycle allocation; most Progyny disputes involve Smart Cycle unit count mismatches, administrative authorization errors, or services rendered outside the authorized cycle dates — these resolve through provider relations, not clinical P2P; when a genuine clinical necessity dispute arises, the escalation path through the assigned case manager is faster than standard written appeal |
How to Prepare the REI Physician for the P2P Call
The single most important determinant of P2P overturn success is how well the REI physician is prepared before the call. Payer medical directors conducting P2P calls for fertility denials have reviewed the same case from the same payer policy perspective before picking up the phone — and an REI physician who enters the call without the specific denial criteria, the patient's matching clinical documentation, and published literature support is at an informational disadvantage from the opening minute. The billing team's role is to prepare a one-page P2P briefing document for the physician that covers the four elements the payer medical director will evaluate: the specific denial criteria cited in the UM determination letter, the patient's clinical data that addresses each criterion, the payer's own policy language that supports coverage for this patient, and any ASRM or peer-reviewed literature that is directly applicable to the patient's diagnosis and clinical situation.
- UM denial determination letter: provide the physician with a copy of the full UM denial letter, not just the EOB, because the UM letter specifies the exact clinical criteria the payer determined were unmet — the EOB states the financial outcome but does not provide the clinical rationale; the P2P call must be structured around the specific unmet criteria cited in the UM letter, not around a general defense of IVF as appropriate treatment
- Payer policy document excerpt: print or pull up the specific subsection of the payer's clinical policy bulletin or coverage determination guideline that applies to this patient's diagnosis; highlight the exact criteria that the payer cited as unmet and the adjacent criteria the patient does meet, so the physician can address both the payer's stated concern and the surrounding criteria that support coverage
- Patient clinical summary on one page: document the patient's primary diagnosis with ICD-10 code, duration of infertility with exact month count, all prior fertility treatments attempted (IUI cycle count with dates, protocols, and outcomes), relevant diagnostic results (AMH, AFC, semen analysis, HSG, operative reports), and the clinical rationale for IVF — keep this to a single page that the physician can reference during the call without needing to scroll through the full chart
- Prior authorization and claims history: confirm whether a prior authorization was obtained, the authorization number and dates if applicable, and any prior claims for fertility services submitted for this patient at this payer — the payer medical director may reference the claims history during the call, and the physician should know if there were prior cycles covered, prior denials, or prior authorizations that were issued and subsequently questioned
- Published clinical literature if applicable: for non-standard clinical situations such as recurrent pregnancy loss, premature ovarian insufficiency in women under 35, severe male factor azoospermia requiring TESE, or Stage IV endometriosis, prepare a one-paragraph summary of the ASRM Practice Committee guideline or peer-reviewed literature most directly applicable to the patient's case; payer medical directors give weight to ASRM guidelines specifically because ASRM is the recognized specialty society authority, and citing an ASRM guideline section number during the call gives the medical director a policy justification for reversal that is defensible within the payer's quality review system
- Specific ask at the close of the call: coach the physician to end the call with a direct, specific request — not "I hope you'll consider this" but "Based on the clinical documentation I've described, I am requesting that you reverse the UM denial and issue a prior authorization for CPT 58970 and CPT 58974 for [patient name], authorization effective for services beginning [date]"; the medical director must take an action at the end of a P2P call, and a specific request with CPT codes and effective dates makes it easier for the medical director to enter the authorization in the UM system before hanging up
Common Fertility Denial Reasons and How to Address Them in the P2P Call
| Denial Reason | Payers Most Likely to Use | What the Payer MD Is Looking For | P2P Talking Points and Documentation to Reference |
|---|---|---|---|
| Insufficient infertility duration — 12-month requirement not met for patient under 35 | Aetna (CPB 0327), UHC (CDG CS-0037.D), most BCBS state plans | Documentation of 12 consecutive months of unprotected intercourse without conception for patients under 35, or 6 months for patients 35–37, with diagnosis-specific exceptions | If the patient has a diagnosis-specific exception (e.g., bilateral tubal occlusion, POI, severe male factor azoospermia) that makes the duration requirement clinically inapplicable, cite the exception directly from the payer's own policy language by section and page number; if no exception applies, provide the patient's documented sexual history from the clinical record showing the actual duration and explain any clinical factor that delayed diagnosis and treatment |
| Prior IUI failure not documented — insufficient IUI cycle count for the covered diagnosis | Aetna, UHC, Cigna — all require 3–6 documented failed IUI cycles with ovarian stimulation for diagnoses where IUI is clinically appropriate (N97.0 anovulatory infertility, unexplained infertility N97.9) | Clinical notes or cycle summary reports documenting the number of IUI cycles attempted, ovarian stimulation protocol used, peak follicle count and estradiol levels on trigger day, insemination date, sperm preparation parameters, and documented outcome (negative beta hCG) for each cycle | Provide cycle summary data for each prior IUI during the call; if fewer than the required number of IUI cycles were attempted, explain the clinical reason IUI was discontinued — most payer policies include a waiver provision for IUI failure when the physician documents a clinical contraindication to continuing IUI such as progressive diminished ovarian reserve, declining sperm parameters, or patient age advancing toward 40; cite the waiver provision from the payer's policy by name |
| Diagnosis not on covered indications list — ICD-10 code submitted not recognized by payer for IVF coverage | All commercial payers; most common when Z31.83 (encounter for ART) is used instead of the underlying infertility diagnosis, or when an encounter code rather than condition code is submitted | The covered diagnosis list for IVF in the payer's clinical policy, matched against the patient's documented clinical infertility condition | On the call, state the clinically correct ICD-10 code for the patient's condition (e.g., N97.1 for bilateral tubal occlusion, E28.310 for premature ovarian insufficiency) and cite the diagnostic evidence in the chart that supports it; for Aetna, reference CPB 0327 Exhibit A (or equivalent section) listing covered diagnoses; confirm whether a corrected claim resubmission is needed with the corrected ICD-10 code alongside any authorization that the P2P reversal produces |
| Diminished ovarian reserve — AMH or AFC values not provided or not below payer threshold | Aetna, UHC — both explicitly list E28.39 as a covered direct IVF indication when AMH is below 1.0 ng/mL or AFC is below 5–7 follicles; denial occurs when the lab value is not attached to the authorization request | Laboratory report for AMH (Quest, LabCorp, or local lab) with the numeric value, reference range, and date of collection; transvaginal ultrasound report documenting total antral follicle count on cycle day 2–3 | Read the specific AMH value and AFC count from the patient's records during the call; cite Aetna CPB 0327 or UHC CDG CS-0037.D by title and the specific section listing E28.39 as a covered IVF indication without an IUI prerequisite; note that ASRM Practice Committee guidelines define diminished ovarian reserve as a specific indication for IVF and that delaying IVF to attempt additional IUI cycles in a patient with E28.39 and AMH below 1.0 would reduce the patient's probability of a successful live birth outcome |
| Male factor — semen analysis not provided or TMC above the payer's severe male factor threshold | Most commercial payers require total motile count (TMC) below 5 million for severe male factor waiver of IUI step requirement; Aetna and UHC are most specific about threshold values | WHO 6th Edition 2021 semen analysis report with total count, progressive motility percentage, morphology (Kruger strict criteria), and calculated total motile count; report dated within 12 months of the authorization request | State the TMC value from the semen analysis during the call; if TMC is below 5 million, cite the payer's policy language defining severe male factor as a direct IVF indication (bypassing IUI step requirements) and note that insemination cycles with TMC below 5 million have documented clinical success rates too low to represent appropriate first-line treatment; for azoospermia, reference the azoospermia finding directly and note that IUI is physically impossible with zero sperm in the ejaculate |
| Experimental or investigational — PGT-A or ERA billing challenged as not medically necessary | Aetna, Cigna, some BCBS plans — PGT-A (billed under 81479 or carrier-specific code) and ERA (endometrial receptivity array, also billed under 81479 or 86849) are subject to experimental/investigational denial at some payers | Published clinical evidence supporting the specific add-on technology for this patient's clinical indication; ASRM committee opinion on PGT-A or ERA if available | For PGT-A, cite the ASRM Committee Opinion on preimplantation genetic testing (most recent version) and the clinical indication (recurrent pregnancy loss, advanced maternal age, prior aneuploid pregnancy); note that untested embryo transfer in a patient with documented prior aneuploid pregnancies or RPL exposes the patient to ongoing pregnancy loss risk; for ERA, acknowledge that evidence is evolving and focus the P2P argument on the specific patient's prior implantation failures and the clinical rationale for endometrial receptivity assessment before the next transfer |
ICD-10 Diagnoses That Produce the Strongest P2P Arguments
Not all fertility P2P calls start from the same position. Certain ICD-10 diagnoses carry built-in advantages in the P2P setting because they are explicitly recognized as direct IVF indications in the clinical policy documents of every major commercial payer — meaning the payer medical director reviewing the case has a policy-level basis to authorize IVF immediately on the call without needing to make a novel clinical coverage determination. Diagnoses that bypass the IUI step requirement in most payer policies are the strongest P2P candidates because the clinical argument is straightforward: the payer's own policy exempts this patient from the prerequisite that was cited as unmet in the denial. In contrast, diagnoses that do not carry an explicit IUI bypass in the payer's policy require a medical exception argument that depends more heavily on the physician's clinical explanation of why IUI is contraindicated for this specific patient — a stronger argument is possible, but it requires the physician to be more thoroughly prepared.
- E28.310 (Symptomatic premature menopause / premature ovarian insufficiency): the strongest P2P position in fertility billing because POI with FSH above 40 mIU/mL and estradiol below 20 pg/mL makes IUI clinically contraindicated — no payer policy requires IUI step-through before IVF when ovarian failure is confirmed; the P2P argument requires only presenting the lab values confirming FSH elevation and estradiol suppression alongside the patient's age; this diagnosis carries IRO overturn rates above 50% even at written appeal, making it one of the few diagnoses where wrongful denial is arguably a violation of clinical standard of care
- N97.1 (Female infertility due to tubal disease): bilateral tubal occlusion documented by HSG or operative laparoscopy is a near-universal IVF bypass at all major payers; the P2P argument is simple — IUI is anatomically impossible when both tubes are occluded; for hydrosalpinges requiring salpingectomy, cite the published literature demonstrating that untreated hydrosalpinges impair IVF success rates and that salpingectomy is the standard of care; bring the HSG report or operative report reference numbers to the call
- N46.121 / N46.021 (Azoospermia — obstructive or non-obstructive): zero sperm in the ejaculate makes conventional IUI non-contributory; IVF with ICSI (89280/89281) using surgically retrieved sperm is the only viable option; the medical director has no clinical basis to require IUI step-through when there are no sperm to inseminate; bring the semen analysis confirming azoospermia and the urologist or reproductive urology consultation note documenting the retrieval plan
- N80.3 / N80.4 (Endometriosis Stage III / IV): severe endometriosis with documented ovarian endometriomas, extensive adhesive disease, or bilateral tubo-ovarian involvement produces a strong P2P argument for direct IVF access; bring the operative laparoscopy report specifying the endometriosis stage and anatomic findings; cite ASRM's most recent practice guideline on endometriosis-associated infertility, which supports IVF as the preferred treatment for Stage III/IV endometriosis-related infertility
- E28.39 with AMH below 1.0 ng/mL (Other primary ovarian failure / diminished ovarian reserve): Aetna CPB 0327 and UHC CDG CS-0037.D both explicitly list E28.39 with confirmed low AMH as a direct IVF indication; on the P2P call, cite the policy section by title and state that the patient's AMH value meets the threshold specified in the policy; note that delaying IVF to complete additional IUI cycles in a patient with documented DOR would further deplete ovarian reserve and reduce the probability of successful retrieval
- N97.4 with TMC below 5 million (Female infertility associated with severe male factor): when the male partner's total motile count is below 5 million on WHO 6th Edition semen analysis, most payer policies recognize that IUI success rates are too low to represent appropriate first-line treatment; bring the semen analysis with the TMC calculated, note the date it was performed, and cite the payer policy's threshold for severe male factor IUI bypass; for Aetna and UHC, the threshold is typically stated in the policy as total motile count below a specific number — verify against the current policy version before the call
P2P vs. Written Appeal: How to Sequence Them Strategically
Peer-to-peer review and formal written appeal are not mutually exclusive — they can and in many cases should be pursued simultaneously, or the P2P can be conducted first with a written appeal filed as a concurrent backup in case the P2P is unsuccessful. The strategic sequencing depends on the payer, the denial type, and the cycle timing. For prospective denials with an upcoming retrieval date within 10–15 days, the P2P is always the primary strategy because it is the only resolution pathway fast enough to obtain authorization before the retrieval date — a written appeal that takes 30–60 days provides no benefit for a retrieval scheduled in two weeks. File the P2P request immediately and begin the written appeal concurrently so it is ready to submit if the P2P is denied, without losing additional time after a failed P2P outcome.
For retrospective denials — where the service has already been rendered and the dispute is over payment rather than authorization before service — the P2P and written appeal timelines are less urgent, and the written appeal with complete clinical documentation may in some cases be more effective because the clinical reviewers on retrospective appeals are evaluating a complete record rather than making a real-time prospective coverage determination. However, even for retrospective denials, completing a P2P call first — if the P2P window is still open — is advisable because a P2P reversal resolves the claim faster than a written appeal and avoids consuming the first-level appeal in cases where the clinical facts strongly support coverage. If the P2P fails, the physician's conversation with the payer medical director will reveal the specific sticking points in the payer's clinical analysis, which provides valuable intelligence for structuring the subsequent written appeal to address those points directly.
Documenting the P2P Outcome
Every peer-to-peer call — regardless of outcome — must be documented in the practice management system the same day the call is completed. Documentation failures create three specific downstream problems: if the payer medical director issues a verbal authorization reversal on the call but the authorization number is not recorded, the authorization cannot be populated on the resubmitted claim and the claim will deny again for missing authorization; if the P2P is unsuccessful and the written appeal window is also running, the documented P2P date establishes the timeline for escalating to formal appeal without delay; and if the payer later disputes the outcome of the P2P call or claims no reversal was issued, the practice has no documentation to support its position.
- Date and time of the P2P call
- Name, credentials, and direct contact number of the payer medical director who conducted the call
- CPT codes and ICD-10 codes discussed on the call — record the exact service lines that were the subject of the P2P review
- Summary of the clinical arguments presented by the REI physician and the medical director's specific responses to each argument
- Outcome of the call: authorization reversal issued (record the new authorization number, effective date range, and authorized CPT codes), authorization upheld (record the medical director's stated reason for upholding the denial, which will inform the written appeal argument), or call deferred for additional clinical record submission (record the specific documentation the medical director requested and the deadline for submitting it)
- Follow-up actions assigned: if authorization was reversed, assign a specific staff member to confirm the authorization in the payer portal within 24 hours and to resubmit the denied claim with the new authorization number within 3 business days; if authorization was upheld, calendar the first-level written appeal submission date based on the payer's appeal deadline and assign the appeal drafting task
- Name of the billing or authorization staff member who monitored the call, scheduled the call, and prepared the physician briefing document — this documents the support workflow and identifies who owns the follow-up
Tracking P2P Performance as a Billing Metric
Peer-to-peer review performance is a measurable billing metric that should be tracked monthly alongside denial rates, appeal overturn rates, and authorization approval rates. The key P2P metrics are: P2P request rate (percentage of eligible UM denials for which a P2P was requested within the payer window), P2P completion rate (percentage of requested P2P calls that were completed versus missed or cancelled), P2P overturn rate by payer (percentage of completed P2P calls that produced an authorization reversal), and average days from UM denial to P2P completion. A P2P request rate below 80% of eligible denials indicates that the billing team is allowing the P2P window to expire on a material number of cases — the most common causes are failing to identify the P2P window from the UM denial letter, routing the denial to the written appeals team rather than the authorization team, or not briefing the REI physician promptly enough to schedule the call within the payer window.
A P2P overturn rate below 35% across all payers should trigger a review of the physician preparation process — specifically whether the REI physicians conducting the calls are being provided with the payer-specific policy document, the patient-specific clinical summary, and a defined closing ask before each call. Practices that invest in the physician preparation workflow consistently produce P2P overturn rates of 45–55% for fertility denials, compared to rates of 20–30% at practices where the physician is given the denial letter alone and expected to conduct the call without structured preparation. At a practice processing 50 IVF denial P2P calls per year, the difference between a 25% and a 50% overturn rate represents 12–13 additional authorized cycles — a revenue impact that significantly exceeds the staff time required to build and maintain a structured physician preparation workflow.
Related Reading
Have a billing question?
Our team can answer questions specific to your practice's payer mix and procedures.
Book a Free Audit →